4
Changes in Ownership
RECURSION PHARMACEUTICALS, INC. Filed Acc 0001209191-23-048818
Chief Executive Officer sold 58,765 shares at an average $8.81 ($517,442)
- Chief Executive Officer acquired 31,250 shares (option exercise)
- Chief Executive Officer acquired 25,000 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Gibson Christopher · Chief Executive Officer
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-09-06 | Exercise or conversion : show line 1 in the form | +31,250 | $2.48 | $77,500 | 905,056 | D |
| 2023-09-06 | Sale : show line 2 in the form | −33,765 | $8.78 | $296,575 | 871,291 | D |
| 2023-09-06 | Conversion : show line 3 in the form | +4,000 | 4,000 | I | ||
| 2023-09-06 | Sale : show line 4 in the form | −4,000 | $8.83 | $35,335 | 0 | I |
| 2023-09-06 | Conversion : show line 5 in the form | +20,000 | 20,000 | I | ||
| 2023-09-06 | Sale : show line 6 in the form | −20,000 | $8.83 | $176,696 | 0 | I |
| 2023-09-06 | Conversion : show line 7 in the form | +1,000 | 1,000 | I | ||
| 2023-09-06 | Sale : show line 8 in the form | −1,000 | $8.84 | $8,836 | 0 | I |
| Open-market sales · 58,765 sh · avg $8.81 · $517,442 | ||||||
Table II: Derivative
4 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-09-06 | Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) | −31,250 | $2.48 | 2030-12-30 | 31,250 | 500,000 | D |
| 2023-09-06 | Conversion : show line 10 in the form Class B Common Stock | −4,000 | $0.00 | 4,000 | 523,000 | I | |
| 2023-09-06 | Conversion : show line 11 in the form Class B Common Stock | −20,000 | $0.00 | 20,000 | 448,000 | I | |
| 2023-09-06 | Conversion : show line 12 in the form Class B Common Stock | −1,000 | $0.00 | 1,000 | 120,875 | I |
Loading xslF345X05/doc4.xml…